Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal ArticleDOI
The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factors
TL;DR: The objective is to evaluate the characteristics and prognostic factors of Japanese patients with lymphangioleiomyomatosis (LAM) and to establish a smoking cessation strategy for patients with LAM.
Journal ArticleDOI
Pulmonary alveolar proteinosis.
TL;DR: The survival rates for adult PAP patients seem to have increased progressively in the four decades since the initial clinical description, and the prognosis for adult patients with PAP varies, but disease-specific survival rate exceeds 80% at 5 years.
Journal ArticleDOI
Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis.
Kanji Uchida,Kanji Uchida,Koh Nakata,Brenna Carey,Claudia Chalk,Takuji Suzuki,Takuro Sakagami,Diana E. Koch,Carrie Stevens,Yoshikazu Inoue,Yoshitsugu Yamada,Bruce C. Trapnell,Bruce C. Trapnell +12 more
TL;DR: Results demonstrate that serum GMAb measurement using the GMAb ELISA was accurate, precise, reliable, had an acceptable LLOQ, and could be accurately expressed in standardized units, and introduce a new unit of measure to enable standardized reporting of serumGMAb data from different laboratories.
Journal ArticleDOI
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Luca Richeldi,Vincent Cottin,Kevin R. Flaherty,Martin Kolb,Yoshikazu Inoue,Ganesh Raghu,Hiroyuki Taniguchi,David M. Hansell,Andrew G. Nicholson,Florence Le Maulf,Susanne Stowasser,Harold R. Collard +11 more
TL;DR: The INPULSIS™ trials will determine the efficacy of nintedanib in patients with IPF, including its impact on disease progression as defined by decline in FVC, acute exacerbations and health-related quality of life.
Journal ArticleDOI
Comparative Study of High-Resolution CT Findings Between Autoimmune and Secondary Pulmonary Alveolar Proteinosis
Haruyuki Ishii,Bruce C. Trapnell,Ryushi Tazawa,Yoshikazu Inoue,Masanori Akira,Yoshihito Kogure,Keisuke Tomii,Toshinori Takada,Masayuki Hojo,Toshio Ichiwata,Hajime Goto,Koh Nakata +11 more
TL;DR: Typical HRCT scan findings for autoimmune PAP patients were GGO with a patchy geographic pattern, subpleural sparing, crazy-paving appearance, and predominance in the lower lung field.